Message from the CEO

Promise: A word that speaks both to our potential as a company and to the commitment we make to patients worldwide.

Celgene is committed to helping patients around the world who suffer from a wide range of debilitating diseases and disorders, including cancer and inflammatory conditions.

Our commitment to medical progress goes hand in hand with our pledge to patients: All who can benefit from our discoveries should have the opportunity to do so. That promise extends to doctors and to the community of caregivers who work on patients’ behalf.

We are convinced that our expertise and dedication, together with our innovative and expanding pipeline of unique compounds, will continue to advance the promise and potential of Celgene as we strive to meet the unmet medical needs of patients the world over. The Celgene pipeline is a promise in itself. It represents new possibilities … and new hope … for hundreds of thousands of people around the world.

The Company is emerging as a globally integrated and culturally diverse biopharmaceutical company. Internationally, we continue to build our global infrastructure and establish operations throughout Europe as well as Japan, Canada and Australia.

Australia represents an important part of our global expansion, having already contributed significantly to the clinical development of Revlimid. We look forward to growing our presence in the region and expanding our collaborative efforts with the Australian medical community in the near future.

Our promise is global in scope. Our commitment to patients extends around the world. The people of Celgene are working every day to fulfill that promise.

Sol J. Barer, Ph.D. Chairman and CEO